Katherine Stueland Sells 17,179 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 17,179 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $76.80, for a total value of $1,319,347.20. Following the completion of the sale, the chief executive officer owned 58,447 shares in the company, valued at $4,488,729.60. This trade represents a 22.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, March 4th, Katherine Stueland sold 25,459 shares of GeneDx stock. The shares were sold at an average price of $78.61, for a total value of $2,001,331.99.
• On Thursday, January 29th, Katherine Stueland sold 1,653 shares of GeneDx stock. The shares were sold at an average price of $94.00, for a total transaction of $155,382.00.

GeneDx Stock Down 6.4%

WGS opened at $70.69 on Thursday. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -94.25 and a beta of 2.03. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46. The firm’s 50-day simple moving average is $92.64 and its 200-day simple moving average is $119.65. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $170.87.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.03. The firm had revenue of $120.99 million during the quarter, compared to the consensus estimate of $120.80 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. Equities research analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its position in shares of GeneDx by 4.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after acquiring an additional 52,322 shares during the last quarter. Vanguard Group Inc. boosted its holdings in GeneDx by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock valued at $154,650,000 after acquiring an additional 18,647 shares during the last quarter. Franklin Resources Inc. increased its position in GeneDx by 60.4% in the fourth quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after purchasing an additional 411,607 shares during the period. Westfield Capital Management Co. LP raised its holdings in GeneDx by 87.1% during the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after purchasing an additional 474,167 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in GeneDx by 59.2% during the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after purchasing an additional 292,394 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on WGS shares. Canaccord Genuity Group boosted their target price on GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Wells Fargo & Company upgraded GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 price objective for the company in a research report on Monday, February 9th. Zacks Research raised GeneDx from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 25th. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a report on Wednesday, January 21st. Finally, Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and a consensus target price of $150.71.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.